Bayer says Monsanto-Syngenta deal would prompt industry review
“It would definitely force a review of how everybody is going to react,” Liam Condon said in a Bloomberg.com phone interview from the division’s headquarters in Monheim, Germany. “There’s only six research and development based players in this industry so if the two biggest were to go together, inevitably it would force others to review their strategies.”
After its first $45 billion bid for Syngenta was rejected, Monsanto is lobbying the Swiss company’s shareholders to put pressure on management to start talks. Bayer, in the process of selling its diabetes-device unit and listing its plastics business, generally likes to play an active role in consolidation rather than just be a bystander, Condon said, while declining to comment on what the company would do in the case of a combination of the two rivals.
Click here for the complete article at Bloomberg.com
Source: BloomBerg.com